Humana Inc. (NYSE: HUM) has partnered with Tuesday Health to launch a new palliative care program in Texas, scheduled for June 1, 2026, aiming to provide comprehensive support for individuals with serious illnesses.
The company reported significant financial figures in its most recent quarter, including $32.52 billion in total revenue, though operating expenses of $4.82 billion exceeded its gross profit of $3.79 billion.
Market analysts offer varied perspectives on Humana's stock, with Evercore ISI raising its price target to $195, while Mizuho Securities lowered its target to $258, still suggesting a potential 30.05% upside from the stock's price of $198.39.
Humana Inc. (NYSE: HUM) is a prominent American health insurance company that provides a range of health and wellness services. The company has announced a new partnership with Tuesday Health to expand access to palliative care. This program aims to support members in Texas who are living with serious illnesses, with a scheduled launch on June 1, 2026.
The initiative focuses on providing whole-person support that can be given alongside curative treatments, not just at the end of life. This approach helps manage symptoms and align care with patient goals. As noted by the Center to Advance Palliative Care, this partnership addresses a significant need, with over 12 million Americans currently living with a serious illness, highlighting the importance of such healthcare partnerships.
This strategic expansion occurs as Humana reports large-scale financial figures. In its most recent quarter, the company recorded total revenue of $32.52 billion. After covering the cost of revenue of $28.72 billion, its gross profit stood at $3.79 billion. However, operating expenses for the same period were higher at $4.82 billion, impacting the company's overall profitability.
Looking at its performance over the last year, Humana’s operating profit margin was 1.12%. This key financial metric shows that the company earns about 1.12 cents in profit from its main operations for every dollar of sales. Its asset turnover ratio of 2.66 suggests it is efficient at using its assets, like its $2.72 billion in equipment, to generate revenue effectively.
Market analysts present varied outlooks on Humana. An analyst from Evercore ISI raised their price target, which is a prediction of a stock's future price, to $195. In contrast, Mizuho Securities lowered its target to $258 from $310, which still suggests a potential 30.05% upside from the stock's price of $198.39 at the time, offering a mixed but generally positive stock outlook.
